CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Landos Biopharma, Inc. - LABP CFD

21.40
0.47%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.27
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Landos Biopharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 21.3
Open* 21.35
1-Year Change* 5518.42%
Day's Range* 21.3 - 21.65
52 wk Range 0.21-1.37
Average Volume (10 days) 72.96K
Average Volume (3 months) 3.98M
Market Cap 9.67M
P/E Ratio -100.00K
Shares Outstanding 31.17M
Revenue N/A
EPS -0.70
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Aug 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 21.30 0.00 0.00% 21.30 21.54 21.30
Mar 26, 2024 21.35 -0.15 -0.70% 21.50 21.58 21.30
Mar 25, 2024 21.35 -0.10 -0.47% 21.45 21.75 20.96
Mar 22, 2024 7.76 0.09 1.17% 7.67 7.93 7.42
Mar 21, 2024 7.52 0.36 5.03% 7.16 7.63 6.92
Mar 20, 2024 6.99 -0.16 -2.24% 7.15 7.15 6.87
Mar 19, 2024 7.07 0.40 6.00% 6.67 7.07 6.38
Mar 18, 2024 6.44 0.09 1.42% 6.35 6.49 6.35
Mar 15, 2024 6.53 0.22 3.49% 6.31 6.54 6.22
Mar 14, 2024 6.25 -0.18 -2.80% 6.43 6.49 6.19
Mar 13, 2024 6.38 0.09 1.43% 6.29 6.53 6.28
Mar 12, 2024 6.31 0.27 4.47% 6.04 6.31 6.04
Mar 11, 2024 6.19 -0.06 -0.96% 6.25 6.29 5.94
Mar 8, 2024 6.10 -0.28 -4.39% 6.38 6.38 6.01
Mar 7, 2024 6.29 -0.20 -3.08% 6.49 6.49 6.11
Mar 6, 2024 6.55 0.03 0.46% 6.52 6.61 6.52
Mar 5, 2024 6.50 0.10 1.56% 6.40 6.57 6.39
Mar 4, 2024 6.51 0.28 4.49% 6.23 6.51 6.23
Mar 1, 2024 6.27 -0.04 -0.63% 6.31 6.31 6.23
Feb 29, 2024 6.23 0.02 0.32% 6.21 6.48 6.17

Landos Biopharma, Inc. Events

Time (UTC) Country Event
Friday, May 10, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Landos Biopharma Inc Earnings Release
Q1 2024 Landos Biopharma Inc Earnings Release

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

13:00

Country

US

Event

Landos Biopharma Inc Annual Shareholders Meeting
Landos Biopharma Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 18 0 0 0
Total Operating Expense 40.561 56.816 30.676 13.29 7.939
Selling/General/Admin. Expenses, Total 14.581 15.252 5.338 1.478 1.136
Research & Development 25.68 41.564 25.338 11.812 6.803
Operating Income -40.561 -38.816 -30.676 -13.29 -7.939
Interest Income (Expense), Net Non-Operating 0.026 -0.018 0.077 -0.337 -0.11
Other, Net 1.259 0.412 0.455 0.16 2.005
Net Income Before Taxes -39.276 -38.422 -30.144 -13.467 -6.044
Net Income After Taxes -39.276 -38.422 -30.144 -13.467 -6.044
Net Income Before Extra. Items -39.276 -38.422 -30.144 -13.467 -6.044
Net Income -39.276 -38.422 -30.144 -13.467 -6.044
Income Available to Common Excl. Extra. Items -39.276 -38.422 -30.144 -13.467 -6.044
Income Available to Common Incl. Extra. Items -39.276 -38.422 -30.144 -13.467 -6.044
Diluted Net Income -39.276 -38.422 -30.144 -13.467 -6.044
Diluted Weighted Average Shares 40.2549 37.5585 40.1176 39.1632 39.1632
Diluted EPS Excluding Extraordinary Items -0.97568 -1.02299 -0.75139 -0.34387 -0.15433
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.96823 -1.02299 -0.75139 -0.34387 -0.15433
Revenue 0 18
Unusual Expense (Income) 0.3
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 6.479 6.513 7.829 11.266 14.953
Selling/General/Admin. Expenses, Total 3.153 3.099 2.967 4.662 3.853
Research & Development 3.326 3.414 4.862 6.604 10.8
Operating Income -6.479 -6.513 -7.829 -11.266 -14.953
Interest Income (Expense), Net Non-Operating -0.004 0 0 0.025 0.001
Other, Net 0.449 1.281 -0.067 -0.043 0.088
Net Income Before Taxes -6.034 -5.232 -7.896 -11.284 -14.864
Net Income After Taxes -6.034 -5.232 -7.896 -11.284 -14.864
Net Income Before Extra. Items -6.034 -5.232 -7.896 -11.284 -14.864
Net Income -6.034 -5.232 -7.896 -11.284 -14.864
Income Available to Common Excl. Extra. Items -6.034 -5.232 -7.896 -11.284 -14.864
Income Available to Common Incl. Extra. Items -6.034 -5.232 -7.896 -11.284 -14.864
Diluted Net Income -6.034 -5.232 -7.896 -11.284 -14.864
Diluted Weighted Average Shares 64.8423 40.2549 40.2549 40.2549 40.2549
Diluted EPS Excluding Extraordinary Items -0.09306 -0.12997 -0.19615 -0.28031 -0.36925
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.09306 -0.12997 -0.19615 -0.28031 -0.36179
Revenue 0 0 0
Unusual Expense (Income) 0 0 0 0.3
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 45.253 92.146 29.888 50.11 2.492
Cash and Short Term Investments 44.402 90.88 28.134 49.965 0.359
Cash & Equivalents 36.64 8.305 2.416 9.808 0.359
Short Term Investments 7.762 82.575 25.718 40.157 0
Total Receivables, Net 0.154 0.001 2.092
Prepaid Expenses 0.851 1.266 0.202 0.144 0.041
Total Assets 45.253 92.879 30.332 50.48 2.796
Property/Plant/Equipment, Total - Net 0 0.707 0.444 0.359 0.304
Property/Plant/Equipment, Total - Gross 0.166 1.248 0.793 0.571 0.413
Accumulated Depreciation, Total -0.166 -0.541 -0.349 -0.212 -0.109
Other Long Term Assets, Total 0 0.026 0 0.011 0
Total Current Liabilities 6.122 16.611 11.034 3.026 1.796
Accounts Payable 3.435 12.908 8.606 2.048 1.692
Accrued Expenses 2.687 3.703 1.939 0.978 0.104
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 6.122 16.611 11.31 3.026 1.796
Total Long Term Debt 0 0 0 0 0
Total Equity 39.131 76.268 19.022 47.454 1
Redeemable Preferred Stock 0 0 73.037 73.037 0.032
Common Stock 0.403 0.403 0.071 0.063 0.059
Additional Paid-In Capital 172.212 170.241 1.633 0.016 10.044
Retained Earnings (Accumulated Deficit) -133.427 -94.151 -55.729 -25.585 -9.135
Other Equity, Total -0.057 -0.225 0.01 -0.077 0
Total Liabilities & Shareholders’ Equity 45.253 92.879 30.332 50.48 2.796
Total Common Shares Outstanding 40.2549 40.2549 40.1176 39.1632 39.1632
Other Current Assets, Total 0 1.398
Other Current Liabilities, Total 0 0.489
Other Liabilities, Total 0 0.276
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 51.184 45.253 49.488 58.038 77.359
Cash and Short Term Investments 50.006 44.402 47.991 55.751 73.796
Cash & Equivalents 45.244 36.64 28.88 19.241 11.288
Short Term Investments 4.762 7.762 19.111 36.51 62.508
Total Receivables, Net
Prepaid Expenses 1.178 0.851 1.497 2.287 3.563
Other Current Assets, Total
Total Assets 51.184 45.253 49.488 58.038 77.61
Property/Plant/Equipment, Total - Net 0 0 0 0.251
Total Current Liabilities 4.16 6.122 5.475 6.51 15.507
Accounts Payable 2.298 3.435 3.204 4.711 9.803
Accrued Expenses 1.862 2.687 2.271 1.799 5.704
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total
Total Liabilities 4.16 6.122 5.475 6.51 15.507
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total
Total Equity 47.024 39.131 44.013 51.528 62.103
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.312 0.403 0.403 0.403 0.403
Additional Paid-In Capital 186.094 172.212 172.016 171.816 171.182
Retained Earnings (Accumulated Deficit) -139.461 -133.427 -128.195 -120.299 -109.015
Other Equity, Total 0.079 -0.057 -0.211 -0.392 -0.467
Total Liabilities & Shareholders’ Equity 51.184 45.253 49.488 58.038 77.61
Total Common Shares Outstanding 31.1684 40.2549 40.2549 40.2549 40.2549
Other Long Term Assets, Total 0 0 0
Property/Plant/Equipment, Total - Gross 0.166 0.575 1.041 1.125
Accumulated Depreciation, Total -0.166 -0.575 -1.041 -0.874
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -39.276 -38.422 -30.144 -13.467 -6.044
Cash From Operating Activities -45.771 -27.061 -22.962 -9.874 -6.896
Cash From Operating Activities 0.577 0.196 0.137 0.103 0.08
Non-Cash Items 3.002 5.274 1.174 0.213 0.369
Cash Interest Paid 0 0.027 0.004
Changes in Working Capital -10.074 5.891 5.871 3.277 -1.301
Cash From Investing Activities 74.06 -58.706 14.131 -40.325 -0.043
Capital Expenditures -0.007 -0.44 -0.181 -0.158 -0.043
Other Investing Cash Flow Items, Total 74.067 -58.266 14.312 -40.167 0
Cash From Financing Activities 0 91.607 1.518 59.648 5
Issuance (Retirement) of Stock, Net 0 93.514 1.518 51.668 5
Issuance (Retirement) of Debt, Net 0 7.98 0
Net Change in Cash 28.335 5.889 -7.392 9.449 -1.939
Foreign Exchange Effects 0.046 0.049 -0.079
Financing Cash Flow Items 0 -1.907
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -6.034 -39.276 -34.044 -26.148 -14.864
Cash From Operating Activities -8.17 -45.771 -42.072 -34.499 -16.502
Cash From Operating Activities 0 0.577 0.577 0.577 0.353
Non-Cash Items 0.256 3.002 2.82 2.238 1.381
Changes in Working Capital -2.392 -10.074 -11.425 -11.166 -3.372
Cash From Investing Activities 3.104 74.06 62.589 45.377 19.506
Capital Expenditures 0 -0.007 -0.007 -0.007 -0.007
Other Investing Cash Flow Items, Total 3.104 74.067 62.596 45.384 19.513
Cash From Financing Activities 13.666 0 0 0 0
Issuance (Retirement) of Stock, Net 13.666 0 0 0 0
Net Change in Cash 8.604 28.335 20.575 10.936 2.983
Foreign Exchange Effects 0.004 0.046 0.058 0.058 -0.021
Financing Cash Flow Items 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Landos Biopharma, Inc. Company profile

About Landos Biopharma Inc

Landos Biopharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. The Company through its artificial intelligence (AI)-based precision medicine platform, LANCE platform, identifies therapeutic targets based on predictions of immunometabolic function and create therapeutic candidates to engage those targets in areas of unmet medical need. Its platform discovers small molecule therapeutics for patients with autoimmune diseases that targets mechanisms of action, including LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. It identifies novel immunometabolic targets and product candidates across indications, such as ulcerative colitis (UC), Crohn’s disease (CD), eosinophilic esophagitis (EoE), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its Omilancor is an oral, gut restricted LANCL2 agonist in development for the treatment of UC, CD and EoE.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Landos Biopharma Inc revenues increased from $0K to $18M. Net loss decreased 3% to $18.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.48 to -$0.57.

Industry: Biotechnology & Medical Research (NEC)

1800 Kraft Drive, Suite 216
24060

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.63 Price
+2.040% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

70,871.20 Price
+2.740% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading